Enteral and supplemental parenteral nutrition enriched with omega-3 polyunsaturated fatty acids in intensive care patients - A randomized, controlled, double-blind clinical trial.
DHA
EPA
Fish oil
Intensive care
Oxygenation
Supplemental parenteral nutrition
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
21
01
2021
revised:
15
03
2021
accepted:
23
03
2021
pubmed:
2
5
2021
medline:
28
8
2021
entrez:
1
5
2021
Statut:
ppublish
Résumé
Enteral nutrition (EN) and parenteral nutrition (PN) enriched with omega-3 polyunsaturated fatty acids (PUFA) have beneficial effects in critical illness. This study aimed to assess the combined effect of EN and supplemental PN enriched with omega-3 PUFA on blood oxygenation in intensive care unit (ICU) patients. Single-center, prospective, randomized, controlled, double-blind, phase III trial conducted from 10/2013 to 11/2017. A total of 100 ICU patients (18-85 years, APACHE II score > 15) requiring mechanical ventilation were randomly assigned to received combined EN and PN either with omega-3 PUFA (omega-3 group) or without (control group) for up to 28 days. Primary endpoint: 'change of PaO Combined EN and PN covered energy requirements to more than 80%. Blood oxygenation (ΔPaO Enteral and supplemental PN both enriched with omega-3 PUFA did not improve lung function but allowed earlier weaning from catecholamine treatment and PN. Supplemental PN succeeded to adequately cover energy requirements in critically ill patients. www.clinicaltrials.gov, registration number: NCT01162928.
Sections du résumé
BACKGROUND & AIMS
Enteral nutrition (EN) and parenteral nutrition (PN) enriched with omega-3 polyunsaturated fatty acids (PUFA) have beneficial effects in critical illness. This study aimed to assess the combined effect of EN and supplemental PN enriched with omega-3 PUFA on blood oxygenation in intensive care unit (ICU) patients.
METHODS
Single-center, prospective, randomized, controlled, double-blind, phase III trial conducted from 10/2013 to 11/2017. A total of 100 ICU patients (18-85 years, APACHE II score > 15) requiring mechanical ventilation were randomly assigned to received combined EN and PN either with omega-3 PUFA (omega-3 group) or without (control group) for up to 28 days. Primary endpoint: 'change of PaO
RESULTS
Combined EN and PN covered energy requirements to more than 80%. Blood oxygenation (ΔPaO
CONCLUSIONS
Enteral and supplemental PN both enriched with omega-3 PUFA did not improve lung function but allowed earlier weaning from catecholamine treatment and PN. Supplemental PN succeeded to adequately cover energy requirements in critically ill patients.
TRIAL REGISTRATION
www.clinicaltrials.gov, registration number: NCT01162928.
Identifiants
pubmed: 33932802
pii: S0261-5614(21)00181-3
doi: 10.1016/j.clnu.2021.03.034
pii:
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Banques de données
ClinicalTrials.gov
['NCT01162928']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2544-2554Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest PS received speaker fees. All the other authors do not declare any conflict of interest.